GPX4-IN-19
GPX4-IN-19 is an effective GPX4 inhibitor (IC50 = 0.311 μM), covalently binds to the Sec 46 site of GPX4. GPX4-IN-19 shows strong anti-proliferative activity with high ferroptosis selectivity. GPX4-IN-19 causes intracellular Fe²⁺ accumulation, leading to increased levels of lipid peroxides (LPOs) and reactive oxygen species (ROS), which induces ferroptosis and subsequently results in DNA damage. GPX4-IN-19 can be used for the study of Triple-Negative Breast Cancer (TNBC) [1].
Product Specifications
CAS Number
3102894-57-2
UNSPSC
12352005
Target
DNA/RNA Synthesis; Ferroptosis; Glutathione Peroxidase; Lipoxygenase; Reactive Oxygen Species (ROS)
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Applications
Cancer-programmed cell death
Field of Research
Cancer
Concentration
10mM
Purity
99.45
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
COC1=CC(N(C(CCl)=O)CC2=CC3=C(OCCO3)C=C2)=CC(OC)=C1F
Molecular Formula
C19H19ClFNO5
Molecular Weight
395.81
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD31 / PECAM-1 (C31.10), CF660R conjugate, 0.1mg/mL
